J.P. Morgan Asset Management today released its seventh annual Global Alternatives Outlook, providing a 12-to-18 month ...
What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...
Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ...
CF Industries (NYSE:CF) -6.8% in Friday's trading as J.P. Morgan downgrades shares to Underweight from Neutral with a $75 ...
Kaguya Komatsu has been named the first female CEO of J.P. Morgan Asset Management -Japan, succeeding Shoichi Ohkoshi, who ...
This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...
J.P.Morgan estimated spending on data centers could contribute between 10-20 basis points to U.S. economic growth in ...
As the J.P. Morgan Healthcare Conference enters its second day, we're tracking presentations from GSK, Novartis, Sanofi, Eli ...
Boss also lowered his FY gross margin to 58.8%, representing a 70-basis point decline year-over-year, attributed to headwinds ...
Health care executives continue to reimagine and reshape their organizations. Their ideas were developing in real time during ...
J.P. Morgan analyst Ranjan Sharma maintained a Buy rating on Grab (GRAB – Research Report) on January 21 and set a price target of $5.60. The ...
J.P. Morgan analyst Mark Strouse maintained a Hold rating on Bloom Energy (BE – Research Report) yesterday and set a price target of $16.00.